Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Explosions heard across Tehran after IDF announces wave of strikes on regime terror targets- Unfathomable and Entertaining Legal disputes That Surprise everyone
- Giude to Best Web based Learning Stage
- Vote In favor of Your Favored Keeping an eye on
- Journalist reported killed in the Gaza Strip
- Polar bears are rewiring their own genetics to survive a warming climate
- Understanding Preschool Projects: Cultivating Abilities and Advancement
- NASA's SPHEREx telescope completes its 1st cosmic map of the entire sky and it's stunning!
- Mussolini's summer villa on Adriatic coast sold for €1.2 million
